Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)

Inclusion Criteria: * Stable adult kidney transplant recipients on maintenance immunosuppression, \>=12 months after kidney transplantation; stable is defined as no need for diagnostic and therapeutic interventions (e.g. kidney biopsy) * Tacrolimus-based immunosuppression in combination with mycophenolic acid or azathioprine and maintenance prednisolone (\<= 5 mg/q.d.) for at least 3 months * Must be \>= 18 years at the time of signing the informed consent * Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. * Able to adhere to the study visit schedule and other protocol requirements. * Subject (male or female) is willing to use highly effective methods during the study treatment (adequate: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). * Females of childbearing potential (FCBP) must agree to pregnancy testing within 7 days from 1st dosing of IMP * To abstain from breastfeeding during study participation and 28 days after study drug discontinuation. * All subjects must agree not to share medication Exclusion Criteria: * patients with known diabetes mellitus or PTDM, or HbA1c\>=6.5% * fasting plasma glucose on examination day (visit 1) of \>= 126 mg/dl (7,0 mmol/l) * patients with c…